ChemicalBook >> journal list >> Biomaterials >>article
Biomaterials

Biomaterials

IF: 12.8
Download PDF

A nanoformulation for immunosuppression reversal and broad-spectrum self-amplifying antitumor ferroptosis-immunotherapy

Published:1 January 2023 DOI: 10.1016/j.biomaterials.2022.121936 PMID: 36502663
Qunfang Yang , Tao Liu , Haiping Zheng , Zechen Zhou , Yan Huang , Honglin Jia , Shixiang Fu , Xuan Zhang , Haigang Zhang , Ya Liu , Xiaohong Chen , Wenjun Shan

Abstract

The efficacy of immunotherapy combined with other therapeutic modalities in the management of cancer has been extensively studied. However, no effective strategy to improve the antitumor effects of immunotherapy at the tumor site has been developed. In this study, we describe a nanoformulation (CP) that integrates ferroptosis-inducing cannabinoid nanoparticles with immunostimulatory Poly(I:C) to enhance antitumor immune responses by activating ferroptosis-immunotherapy pathways. The results indicated that CP nanoformulation effectively induced ferroptosis, cellular immunogenic death, and anti-tumor immune responses which initiate T cell responses leading to the inhibition of established tumors. In addition, CP nanoformulations reversed the tumor immunosuppressive microenvironment and promoted tumor ferroptosis. These results indicated that the self-amplifying nanoformulation may be an effective strategy for broad-spectrum cancer immunotherapy.

Substances (5)

Materials Related products
Procduct Name CAS Molecular Formula Supplier Price
Polyinosinic acid-polycytidylic acid 24939-03-5 C19H27N7O16P2 281 suppliers $22.00-$5053.13
Polyinosinic acid-polycytidylic acid 24939-03-5 C19H27N7O16P2 281 suppliers $22.00-$5053.13
Polyinosinic acid-polycytidylic acid 24939-03-5 C19H27N7O16P2 281 suppliers $22.00-$5053.13
Polyinosinic acid-polycytidylic acid 24939-03-5 C19H27N7O16P2 281 suppliers $22.00-$5053.13

Similar articles

IF:1.8

Toltrazuril effective against a broad spectrum of protozoan parasites.

Parasitology Research H Mehlhorn, G Schmahl,etc Published: 1 January 1988
IF:6.6

Perampanel: Does it have broad-spectrum potential?

Epilepsia Heidrun Potschka, Eugen Trinka,etc Published: 28 June 2018
IF:5.3

Liposomes-mediated enhanced antitumor effect of docetaxel with BRD4-PROTAC as synergist for breast cancer chemotherapy/immunotherapy

International Journal of Pharmaceutics Xixi Chen, Fang Li,etc Published: 19 November 2024